Drug Trial Radar · NCT05320393
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Mar 30, 2022
Primary completion
May 22, 2023
Study completion May 22, 2023
Sponsor
- Lead sponsor
- Evolus, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ethica Clinical Research Inc.
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.
Conditions
- Glabellar Frown Lines
Interventions
PrabotulinumtoxinA-XvfsDrug
One treatment of 40 units
OnabotulinumtoxinADrug
One treatment of 20 units
PrabotulinumtoxinA-XvfsDrug
One treatment of 20 units
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Effect Described by Kaplan-Meier AnalysisTime frame: Duration of effect for each subject will be based on number of days from baseline to the day that Glabellar Line Scale severity (Investigator Assessment) returns to baseline value, assessed every 30 days up to 365 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aesthetic Eyelid Plastic Surgery
Boca Raton, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.